Teleflex Shares Fall After Revised FY22 Outlook Lags Consensus

  • Teleflex Incorporated TFX reported Q2 FY22 revenues of $704.5 million, down 1.3% Y/Y, up 2.3% on a constant currency basis, missing the consensus of $719.50 million.
  • Lower sales from the Interventional Urology segment impacted the revenue. The company did not see the expected operating environment recovery in the Interventional Urology business during the second quarter. 
  • Adjusted diluted EPS increased 1.2% to $3.39, exceeding the consensus of $3.34.
  • The gross margin remained flat at 59%.
  • FY22 Guidance: Teleflex cut GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively.
  • The company lowered adjusted EPS to $13.00 - $13.40 from $13.70 - $14.30, below the consensus of $13.97.
  • Price Action: TFX shares are down 6.53% at $249.13 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!